Table 4.

Hazard ratios for risk of death, relapse or secondary cancer occurence associated with SNPs (p<0.15) in cytokine genes for NHL overall and subtypes (n for NHL=496, DLBCL=155, FL=117, CLL/SLL=34)

Gene	SNP	HR (95% CI) NHL Overall	HR (95% CI) DLBCL	HR (95% CI) FL	HR (95% CI) CLL/SLL
CARD15	rs2066844			0.31 (0.07–1.38)
CCR2	rs1799864			0.39 (0.15–1.05)
CCR5	rs1800940	0.79 (0.60–1.05)			0.39 (0.16–0.95)
CSF2	rs25882				2.63 (0.99–6.97)
CTLA4	rs231775		0.66 (0.39–1.13)		0.49 (0.21–1.15)
CX3CR1	rs3732379	1.26 (0.95–1.67)
FCGR2A	rs1801274		1.78 (1.04–3.04)
IFNGR2	rs1059293				2.51 (0.94–6.74)
IFNGR1	rs3799488	1.33 (0.97–1.83)		2.63 (1.00–6.91)	0.42 (0.14–1.28)
IL4R	rs1805011	1.37 (0.98–1.92)	1.75 (0.88–3.50)	2.14 (0.99–4.64)
IL4R	rs1801275	1.33 (0.99–1.77)		2.53 (1.22–5.21)a
IL5	rs2069812		0.69 (0.42–1.14)
IL5	rs2069807			82.5 (7.15–953.0)
IL6	rs1800797		1.61 (0.91–2.83)
IL6	rs1800796	0.39 (0.22–0.71)a	0.20 (0.05–0.83)a	0.32 (0.09–1.10)
IL7R	rs2228141			1.81 (0.84–3.88)
IL8	rs4073			2.23 (1.03–4.80)
IL8	rs2227307			2.15 (0.99–4.65)
IL8	rs2227306			1.96 (0.93–4.13)
IL8	rs2227538			108.6 (9.0–1313.2)
IL8RA	rs2234671		1.81 (0.90–3.65)
IL8RB	rs1126579	1.25 (0.92–1.68)			3.33(1.35–8.20)
IL12A	rs582054		1.56 (0.88–2.96)
IL12B	rs3212227			1.70 (0.87–3.32)
IL10	rs3024509			2.31 (0.90–5.88)	0.20 (0.04–1.08)
IL16	rs859			1.75 (0.87–3.50)
IL16	rs11325		0.62 (0.33–1.09)
MIF	rs755622			1.86 (0.89–3.89)
SELE	rs5361		0.57 (0.30–1.11)	0.26 (0.09–0.78)a
TGFBR1	rs868		1.85 (1.02–3.33)		0.26 (0.09–0.77)a
VCAM1	rs1041163				2.48 (0.78–7.92)

Reference groups were homozygote wild-type carriers. Models adjusted for age (continuous), education (high school or less, some colleges, and college graduate or more), stage (I, II, III, IV and unknown), B-symptom presence (yes, no, and missing) and initial treatment (none, radiation only, chemotherapy-based regimen, and other)

^aRemains significant at p=0.05 level following FDR adjustment